Since our early days in 2012, we have established a proven track record in precision oncology. Local and international institutions have recognised our continuous growth, empowering our team to redouble efforts to make precision medicine in oncology a reality. Whatever the challenges, we will continue to set the bar high and to disrupt technology in personalised cancer therapy.
Scroll down to discover
Deloitte Belgium granted us for the second time the award of the fastest growing tech company headquartered and founded in Belgium in the biotech and pharma category. “Winning the award multiple times is very rare, as each year the challenge to grow our turnover is more and more difficult”, said Jean-Pol Detiffe, Founder of OncoDNA.press release
We won Deloitte Belgium’s Fast 50 Technology Competition in the healthcare and life sciences category for the first time in 2018. The award recognised OncoDNA as the fastest growing tech company in the field in terms of percentage of growth in turnover over the past four years.press release
The Wallonia Export-Investment Agency (AWEX) awarded us the Tremplin Prize “Grande Exportation". The prize recognised our successful export performance, following our global expansion into over 60 countries most notably beyond Europe. Mr. Paul Magnette, former Wallonia’s Minister-President, was present at the award ceremony.Interview with Jean-Pol Detiffe, OncoDNA Founder
OncoDNA was named “Most Disruptive Innovator” in the rising star category of Deloitte Belgium’s Fast 50 Technology Competition in 2015. The award recognises fast growing companies that have developed a product or services that make very high-end technology accessible for wide application and use.Award ceremony (video)
Ernst & Young celebrated our entrepreneurial achievement by electing us as the Most Promising Company only three years after our foundation in 2012. The global program supports companies that demonstrate vision, leadership and success.Award ceremony (video)
OncoDNA aims to improve care, quality of life and survival of cancer patients. Our scientific team regularly publishes research papers in international journals and presents scientific posters in major cancer congresses to support our clinical expertise in precision oncology.